Which sort of pharma rep would a doctor prefer to see--a live rep, in the flesh, possibly carrying an iPad? Or an electronic version, piped in via Skype at the physician's convenience? Pfizer aims to find out, with its latest foray into e-detailing.
Pfizer's Meridian unit that makes the injector "has received millions of taxpayer dollars for doses of this drug, some of which do not meet specifications," Republican Rep. Andy Harris of Maryland, a physician who practiced at Johns Hopkins Hospital in Baltimore, said in a statement Monday.
Pfizer is an unusual player in the vaccine space. It is the fourth biggest vaccine company by revenue, yet almost wholly reliant on one product--Prevnar 13. At a media event in New York this week, the company's top brass explained how they plan to build out the business in the coming years.
Dako got hit with an FDA citation over what the agency says are quality system manufacturing violations involving one of its signature breast cancer diagnostic kits and other related products.
Even the smallest biotech company can benefit when it thinks and acts globally. And a biotech startup that was able to grab a promising therapeutic asset from Pfizer as it shuttered much of its work in the U.K. has pieced together a global virtual organization that illustrates just how effective that can be.
AbbVie, Shire and Pfizer are unamused and unimpressed by a designer's use of the names of their drugs Vicodin, Adderall and Xanax as a fashion statement. The new T-shirts have struck a nerve even as regulators are in the midst of a national discussion on prescription drug abuse.
Venture firms have traveled a variety of new routes to limit risks and score returns in biotech, and the Wall Street Journal has covered how Clarus Ventures and OrbiMed Advisors have found potentially lucrative ways of investing in the pipelines of established pharma companies.
These alliances benefit not only pharma companies, which gain access to world-class scientists and robust drug discovery programs, but also academic institutions, which increasingly are realizing that relationships with Big Pharma are more and more vital.
In a move that boosted the fortunes of two biotech outfits, Pfizer has elected to continue development of the tamper-resistant painkiller Remoxy with a planned Phase I study, Nasdaq reported.
In the past, the U.K.'s cost-effectiveness gatekeeper has shown that it will bend preliminary draft guidance decisions if the price is right. But for Pfizer, which slashed costs on its targeted lung cancer drug Xalkori in hopes of gaining recommendation for its use in Britain's National Health Service, that price wasn't low enough.